Screening and Treatment of Latent Tuberculosis Infection among Healthcare Workers at a Referral Hospital in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Se Yoon | - |
dc.contributor.author | Lee, Eunyoung | - |
dc.contributor.author | Lee, Eun Jung | - |
dc.contributor.author | Kim, Tae Hyong | - |
dc.contributor.author | Kim, Yang-Ki | - |
dc.date.accessioned | 2021-08-11T08:44:16Z | - |
dc.date.available | 2021-08-11T08:44:16Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.issn | 2092-6448 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3835 | - |
dc.description.abstract | Background: Healthcare workers (HCWs) have a high risk of tuberculosis (TB) infection. Since August 2017, Korea has mandated the testing of latent TB infection (LTBI) and recommended treatment from HCWs at medical institutions. However, the acceptance/completion rate and adverse events of LTBI treatment have not been analyzed. Materials and Methods: From February to August 2017, we conducted a retrospective study at a referral university hospital in Korea, to screen the interferon-gamma release assay (IGRA) tests conducted for all HCWs for detecting and treating LTBI. HCWs diagnosed with LTBI were offered a 9-month isoniazid (9H), 3-month isoniazid/rifampin (3HR), or 4-month rifampin regimen. We investigated the acceptance/completion rate, adverse events, and causes of discontinuation or change in LTBI medication. A major adverse event was one wherein a patient had any adverse event >= grade 3 causing LTBI treatment interruption. Results: Of the 1,538 HCWs, 1,379 underwent IGRA testing for LTBI. Among them, 13.6% (187/1,379) tested positive and 73.3% (137/187) received treatment. The overall completion rate was 97.8% (134/137). HCWs were significantly more likely to complete first-line therapy with 3HR than with 9H (91.4% vs. 76.7%, P = 0.02). The most common major adverse event was hepatotoxicity (n = 7), followed by thrombocytopenia (n = 1) and anaphylactic shock (n = 1). Hepatotoxicity and hepatotoxicity (>= grade 2) were more frequent in 9H than in 3HR (39.5% vs. 17.2%, P = 0.006 and 18.6% vs. 3.7%, P = 0.005, respectively). The median time to hepatotoxicity was 96 days (interquartile range, 20 - 103 days). Conclusion: Completion of first-line therapy for LTBI is more likely with 3HR than with 9H. This might be related to the development of hepatotoxicity after around 3 months of treatment. Anaphylactic shock and platelet count should be carefully monitored in those receiving rifampin-containing regimens. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy | - |
dc.title | Screening and Treatment of Latent Tuberculosis Infection among Healthcare Workers at a Referral Hospital in Korea | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3947/ic.2019.51.4.355 | - |
dc.identifier.scopusid | 2-s2.0-85078167069 | - |
dc.identifier.wosid | 000505078200003 | - |
dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.51, no.4, pp 355 - 364 | - |
dc.citation.title | Infection and Chemotherapy | - |
dc.citation.volume | 51 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 355 | - |
dc.citation.endPage | 364 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002546022 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | RIFAPENTINE | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | HEPATOTOXICITY | - |
dc.subject.keywordPlus | STRATEGY | - |
dc.subject.keywordAuthor | Adverse drug reaction | - |
dc.subject.keywordAuthor | Isoniazid | - |
dc.subject.keywordAuthor | Rifampin | - |
dc.subject.keywordAuthor | Latent tuberculosis infection | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.